Frontlight ResearchEarly access
Prostate cancer trials in Italy
83 of 119 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in ItalyA clinical trial to learn more about the effects of AAA817 given with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
- Where
- Bologna, Meldola, Milan, Pisa, Rozzano
- Age
- 18 years and over
- People
- 265 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-512340-32-01 - Phase 1Not yet taking people in ItalyClinical study to evaluate the safety and efficacy of a new targeted radioactive drug treatment for advanced prostate cancer
- Where
- Milan
- Age
- 18 years and over
- People
- 6
- Run by
- Fondazione IRCCS Istituto Nazionale Dei Tumori
See details and how to join2026-525244-14-00 - Phase 3Not yet taking people in ItalyRelugolix in Patients With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy.
- Where
- Bologna, Milan, Padova, Palermo, Pisa, Ravenna, Roma, Udine, Verona
- Age
- 18 years to 99 years
- People
- 268
- Run by
- Istituto Oncologico Veneto IRCCS
See details and how to joinNCT07927777 · EU 2025-524702-15-00 - Phase 3Taking peopleStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Where
- Meldola, Milan
- Age
- 18 years and over
- People
- 1,310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00 - Phase 1/2Taking peopleTulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Where
- Cremona, Rozzano, Verona
- Age
- 18 years and over
- People
- 181 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07190300 · EU 2025-521873-15-00 - Phase 2Taking peopleA Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
- Where
- Castelfranco Veneto, Milan, Naples, Rome
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07287150 · EU 2025-521327-67-00 - Phase 3Taking peopleDiagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
- Where
- Meldola, Verona
- Age
- 18 years and over
- People
- 434 worldwide
- Run by
- ABX advanced biochemical compounds GmbH
See details and how to joinNCT06122584 - Phase 3Taking peopleA Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Where
- Castelfranco Veneto, Foggia, Milan, Naples, Palermo, Rome, Rozzano, Turin
- Age
- 18 years and over
- People
- 1,203 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07164443 · EU 2025-520927-26-00 - Phase 3Taking peopleA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Where
- Florence, Frattamaggiore, Milan, Rome, Turin
- Age
- 18 years and over
- People
- 800 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07225946 · EU 2025-522713-29-00 - Phase 3Active, not recruitingA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
- Where
- Cremona, Meldola, Milan, Naples, Rome, Rozzano, Terni, Trento, Verona
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Pfizer
See details and how to joinNCT06629779 · EU 2024-511652-40-00 - Phase 3Taking peopleA Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Where
- Arezzo, Foggia, Milan, Rome, Rozzano, Siena, Terni, Verona
- Age
- 18 years and over
- People
- 1,440 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06925737 · EU 2024-517423-40-00 - Phase 1/2Taking peopleEIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- Where
- Rome
- Age
- 18 years and over
- People
- 160 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00 - Phase 1/2Taking peopleStudy of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Where
- Milan
- Age
- 18 years and over
- People
- 205 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07288359 - No phaseTaking people24 Gy in One Fraction Urethral-sparing "HDR Like" SBRT for Prostate Cancer
- Where
- Milan
- Age
- 18 years and over
- People
- 70
- Run by
- IRCCS San Raffaele
See details and how to joinNCT05936736 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Bergamo, Genova, Naples, Verona
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 1Not yet taking people in ItalyA clinical trial to learn about the effects of INR731 alone or with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
- Where
- Milan
- Age
- 18 years and over
- People
- 26 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-524080-20-00 - Phase 1Taking peopleA Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
- Where
- Milan
- Age
- 18 years and over
- People
- 208 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07570979 - Phase 2Taking people"APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIAN".
- Where
- Alba, Arezzo, Bologna, Candiolo, Florence, Foggia, Frattamaggiore, Genoa, Macerata, Misterbianco, Modena, Padova, Parma, Perugia, Reggio Emilia, Rome, Siena, Turin, Udine
- Age
- 18 years and over
- People
- 180
- Run by
- Fondazione Radioterapia Oncologica Onlus
See details and how to join2022-501894-37-00 - Phase 1/2Not yet taking people in ItalyStudy of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
- Where
- Milan, Naples, Rome, Rozzano
- Age
- 18 years to 130 years
- People
- 283 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07181161 · EU 2024-520026-11-00 - Phase 3Taking peopleAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
- Where
- Brescia, Ferrara, Genoa, Milan, Negrar, Pisa, Rome, Rozzano
- Age
- 18 years to 100 years
- People
- 450 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00 - Phase 3Taking peopleA Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Where
- Catania, Foggia, Meldola, Milan, Terni
- Age
- 18 years and over
- People
- 1,314 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136650 · EU 2023-504957-11-00 - Phase 3Taking peopleA Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Where
- Foggia, Milan, Modena, Orbassano, Peschiera del Garda, Rozzano, Trento
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT07213674 - Phase 2Not yet taking people in ItalyPET-Guided Navigation with Electromagnetic Tracking during PSMA-RadioGuided Surgery: Innovative Bimodal Detection of Nodal Metastases in Prostate Cancer Patients
- Where
- Milan
- Age
- 18 years and over
- People
- 54
- Run by
- Ospedale San Raffaele S.r.l.
See details and how to join2026-526915-12-00 - Phase 3Not yet taking people in ItalyAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Where
- Milan, Misterbianco, Naples, Negrar, Reggio Emilia, Rozzano
- Age
- 18 years and over
- People
- 670 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07611110 - No phaseTaking peoplePSMA-Guided Surgery and Tissue-Resident T-Cell Profiling in Node-Positive Prostate Cancer
- Where
- Milan
- Age
- 18 years to 85 years
- People
- 12
- Run by
- Niguarda Hospital
See details and how to joinNCT07879820